Table 4 Font trial: serious adverse events
Event | Adalimumab (N = 7) | Galactose (N = 7) | Standard Therapy (N = 7) | ||||||
|---|---|---|---|---|---|---|---|---|---|
N PTs with events | % Rand PTs | N Events | N PTs with events | % Rand PTs | N events | N PTs with events | % Rand PTs | N events | |
Fatal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Immediate Life Threatening | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Required Hospitalization | 3 | 42.9 | 32 | 1 | 14.3 | 9 | 1 | 14.3 | 1 |
Prolonged Existing Hospitalization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Persistent or Significant Disability/Incapacity | 0 | 0 | 0 | 1 | 14.3 | 1 | 0 | 0 | 0 |
Congenital Anomaly / Birth Defect | 1 | 14.3 | 1 | 1 | 14.3 | 1 | 0 | 0 | 0 |
Causes Cancer | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Overdose of Study Medication | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |